Literature DB >> 7426746

Modern approaches to the treatment of breast cancer.

C K Osborne, W A Knight, M G Yochmowitz, W L McGuire.   

Abstract

Breast cancer is the most common cause of cancer death in women in this country. Until recently, the traditional treatment has been radical surgery with or without radiation therapy for patients with primary breast cancer, and palliative endocrine therapy followed by chemotherapy for patients with advanced disease. These treatments have met with limited effectiveness in terms of eradicating the disease. Studies in the past decade have given cause for optimism for breast cancer patients. Adjuvant systemic therapy after local treatment appears promising for certain subsets of patients with primary breast cancer. The development of estrogen receptor assays has markedly changed our approach to the disease and improved patient care. Estrogen receptor is an important prognostic factor and is useful in planning appropriate therapy for patients with primary breast cancer as well as those with advanced disease. Further research is urgently needed to improve the dismal survival of certain women with this common malignancy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7426746

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

Review 1.  Issues related to choice of breast reconstruction in early-stage breast cancer.

Authors:  Kristina O'Shaughnessy; Neil Fine
Journal:  Curr Treat Options Oncol       Date:  2006-03

2.  Adjuvant therapy of breast cancer: the Southwest Oncology Group experience.

Authors:  W A Knight; S E Rivkin; H Glucksberg; M A Foulkes; J J Costanzi; R L Stephens; J W Athens; R M O'Bryan
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

3.  Correlation of primary breast cancer histopathology and estrogen receptor content.

Authors:  E R Fisher; C K Osborne; W L McGuire; C Redmond; W A Knight; B Fisher; G Bannayan; A Walder; E J Gregory; A Jacobsen; D M Queen; D E Bennett; H C Ford
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

4.  T lymphocyte subsets in the peripheral blood of patients with benign and malignant breast disease.

Authors:  D R McCluskey; A D Roy; W P Abram; W M Martin
Journal:  Br J Cancer       Date:  1983-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.